FLEX Technology Designed to Improve the Patient Experience
Company Initiating U.S. Product Launch
IRVINE, Calif., Dec. 12, 2023 (GLOBE NEWSWIRE) — ReShape Lifesciences ® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the U.S. Food and Drug Administration (FDA) has granted approval of a PMA supplement for the companyâ€
“PMA supplement approval for our next generation Lap-Band ® 2.0 FLEX is a historic event for ReShape that is expected to be a key growth catalyst for the companyâ€
“Based on my 20-year use of the Lap-Band ® , over time, some patients have needed adjustments, particularly when related to urgent loosening to relieve food obstruction,†stated Christine Ren-Fielding, M.D., Professor of Surgery at NYU Grossman School of Medicine, Director of the NYU Langone Weight Management Program and Chief of the Division of Bariatric Surgery. “Lap-Band 2.0 ® FLEX will potentially remedy this issue because of the ability for self-correction, utilizing an internal reservoir system. In addition, multi-modal therapy is becoming a mainstay in the bariatric surgery field. GLP-1 agonists can be used to complement and augment weight loss after surgery to help prevent weight regain.â€
About ReShape Lifesciences ®
ReShape Lifesciences ® is Americaâ€
Forward-Looking Safe Harbor Statement
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as “expect,” “plan,” “anticipate,” “could,” “may,” “intend,” “will,” “continue,” “future,” other words of similar meaning and the use of future dates. Forward-looking statements in this press release include the statement that the PMA supplement approval is expected to be a key growth catalyst for the companyâ€
Dr. Ren-Fielding receives consulting and other compensation from ReShape Lifesciences. Her views are her own and do not represent an endorsement by NYU Langone Health.
CONTACTS
ReShape Lifesciences Investor Contact:
Paul F. Hickey
President and Chief Executive Officer
949-276-7223
ir@ReShapeLifesci.com
Investor Relations Contact:
Rx Communications Group
Michael Miller
(917)-633-6086
mmiller@rxir.com
Disclaimer
This article is for the purposes of solicitation subscriptions for this website. This website expects to generate new advertisement revenue resulting from the distribution of this article. The amount of which is unknown at this time. This website or it’s authors do not own any shares of ReShape Lifesciences Inc. (RSLS) and does not buy, sell, or trade any shares of (RSLS). This article does not provide a professional analysis of a (RSLS) financial position. (RSLS) financial position and all other information regarding the featured Company should be verified directly with (RSLS). Please read our full disclaimer for more detailed information.